Page 162 - Haematologica-April 2018

A.-S. Michallet et al. References
1. Roche Registration Ltd [Internet]. MabThera: Summary of product character- istics; Updated 2017 Nov 6 [cited 2018 Jan 9]. Available from: http://www.ema.europa.eu/docs/en_GB/d ocument_library/EPAR_- _Product_Information/human/000165/WC 500025821.pdf
2. Genentech Inc [Internet]. Rituxan: Highlights of prescribing information; Updated 2016 Apr [cited 2018 Jan 9]. Available from: https://www. gene.com/download/pdf/rituxan_prescrib- ing.pdf.
3. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
4. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression- free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-1765.
5. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and ritux- imab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016-3024.
6. Shah N, Tam C, Seymour JF, Rule S. How applicable is fludarabine, cyclophos- phamide and rituximab to the elderly? Leuk Lymphoma. 2015;56(6):1599-1610.
7. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with ritux- imab for previously untreated patients with chronic lymphocytic leukemia: a multicen- ter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
8. Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236-1241.
9. Foà R, Del Giudice I, Cuneo A, et al. Chlorambucil plus rituximab with or with- out maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89(5):480-486.
10. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
11. Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia.
2015;29(7):1602-1604.
12. Knauf WU, Lissichkov T, Aldaoud A, et al.
Phase III randomized study of bendamus- tine compared with chlorambucil in previ- ously untreated patients with chronic lym- phocytic leukemia. J Clin Oncol. 2009;27(26):4378-4384.
13. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambu- cil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012;159(1):67-77.
14. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
15. Laurenti L, Innocenti I, Autore F, et al. Bendamustine in combination with ritux- imab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real- life practice in Italian hematology depart- ments. Leuk Res. 2015;39(10):1066-1070.
16. Tam CS, O'Brien S, Wierda W, et al. Long- term results of the fludarabine, cyclophos- phamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
17. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
18. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with flu- darabine (F), cyclophosphamide (C), and rit- uximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and ritux- imab (BR) in previously untreated and phys- ically fit patients (pts) with advanced chron- ic lymphocytic leukemia (CLL): final analy- sis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood. 2014;124(21):19.
19. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a ran- domised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873-1883.
20. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v78-84.
21. NCCN [Internet]. NCCN Guidelines for patients: chronic lymphocytic leukemia [cited 2018 Jan 11]. Available from: https://www.nccn.org/patients/guide-
lines/cll/files/assets/common/downloads/fi
les/cll.pdf.
22. Städler N, Shang A, Bosch F, et al. A sys-
tematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chron- ic lymphocytic leukemia. Adv Ther. 2016;33(10):1814-1830.
23. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
24. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus ritux- imab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090-1099.
25. Chanan-Khan A, Cramer P, Demirkan F, et al. HELIOS investigators. Ibrutinib com- bined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chron- ic lymphocytic leukaemia or small lympho- cytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
26. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
27. Roberts AW, Ma S, Brander D, et al. Venetoclax (ABT-199/GDC-0199) com- bined with rituximab induces deep responses in patients with relapsed/refrac- tory chronic lymphocytic leukemia. Haematologica. 2015;100(suppl 1):154(abstr S431).
28. Sharman JP, Coutre SE, Furman RR, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopu- lations with del(17p) and other adverse prognostic factors. Blood. 2014;124(21):330.
29. Robak T, Wach M, Jones JA, et al. Results of a phase 3 randomized controlled study evaluating the efficacy and safety of idelal- isib (idela) in combination with ofatumum- ab (ofa) for previously treated chronic lym- phocytic leukemia (CLL). Haematologica. 2015;100(suppl 1):229(abstr LB598).
30. US Food and Drug Administration [Internet]. FDA alerts healthcare profes- sionals about clinical trials with zydelig (idelalisib) in combination with the other cancer medicines. Drug Safety and Availability; Updated 2016 Mar 14 [cited 2017 Jan 9]. Available from: http://www.fda.gov/Drugs/Drugsafety/uc m490618.htm.
31. Chen Q, Jain N, Ayer T, et al. Economic bur- den of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166-174.
706
haematologica | 2018; 103(4)